考比替尼

考比替尼（CAS 934660-93-2）的公开数据库记录，列此仅供独立核对。

这个物质在各数据库里的编号

数据库记载的用途

• Cobimetinib is indicated in combination with [vemurafenib] for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.
• Cobimetinib is a tyrosine kinase receptor inhibitor that is used in combination with vemurafenib as therapy for selected forms of advanced malignant melanoma. The combination of cobimetinib and vemurafenib is commonly associated with serum enzyme elevations during therapy and to rare instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; MEK Inhibitors
• Cobimetinib fumarate is approved to be used to treat:
• • Melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used with vemurafenib in patients whose cancer has a certain mutation in the BRAF gene.
• • Histiocytic cancers. It is used alone in adults.

它在各数据库里的别名

Cobimetinib; 934660-93-2; GDC-0973; XL518; Cotellic; GDC 0973; Xl-518; RG7420; XL 518; RG 7420; ER29L26N1X; CHEBI:90851; DTXSID60239435; 1-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoyl}-3-[(2S)-piperidin-2-yl]azetidin-3-ol; cobimetinibum; 1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)-3-((2S)-piperidin-2-yl)azetidin-3-ol

计算机算出的分子描述符

数据库摘要

Cobimetinib · CAS 934660-93-2 · C21H21F3IN3O2. UNII ER29L26N1X.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。